Original news and analysis on international IP policy
After two decades of intellectual property regimes in trade agreements, one could have some second thoughts, according to a number of panellists at the Trade and Sustainable Development Symposium, organised by the International Centre for Trade and Sustainable Development (ICTSD) and held alongside the 11th World Trade Organization Ministerial in Buenos Aires, Argentina this week.
The European Union (EU) is currently negotiating a free trade agreement (FTA) with the four founding members of Mercosur (Argentina, Brazil, Paraguay and Uruguay), which comprises a chapter on intellectual property rights (IPR). A new round of negotiations is taking place from November 29th to December 8th in Brussels[1]. Word is that they aim to announce the closure of the agreement at the next World Trade Organization (WTO) Ministerial Conference that will be held from 10-13 of December in Buenos Aires and the clock is ticking to close all the chapters before that. The authors have conducted a study that shows the adoption of the measures proposed by the EU could put the sustainability of access to health policies in Brazil at risk, as they could sharply increase public expenditures on medicines.
It’s hard to escape the watchful eye of the internet – it will follow you through life. But if something put on the internet about you is wrong, misrepresents you or even endangers you, should you have a right to…
Inspiring, generous, humanist, nobody was short of praise and anecdotes at an event last week to celebrate the lifelong contribution of Pedro Roffe, well-known Geneva thinker and writer on intellectual property. A conference on the evolution of intellectual property, trade and development had been organised for the occasion, congregating many IP experts offering their perspective on the role of IP in fields, such as public health, innovation policy, and competition law.
Register Now for The Global Debate on Intellectual Property, Trade and Development: Past, Present and Future - A Conference in Honour of Pedro Roffe, taking place on 15 June at the University of Geneva, Uni-Bastions, Geneva, Switzerland. Registration is open and free, see details.
As negotiations take place this week, an evaluation of the impact of one of the TRIPS-plus measures of the Mercosur/EU FTA on the prices of medicines in Brazil has been released. Based on the draft of the agreement, by their calculations, an additional USD 444 million would be necessary to be spent by the public health system for the purchase of six medicines alone, write Marcela Fogaça Vieira and Gabriela Costa Chaves.
Representatives of Chilean civil society and Congress this week presented the Chilean health minister with a proposal urging the government to take advantage of international trade law and a newly passed congressional resolution to issue compulsory licences on high-priced drugs for hepatitis C and prostate cancer.
Minister Celso Amorim of Brazil has had a significant impact on the state of global negotiations in his professional lifetime, including on global intellectual property rights.
On 12 December, the Argentinian Copyright Office and the Ministry of Culture invited a group of stakeholders, among which was this author, to discuss the final draft of the Exceptions and Limitations Bill (Proyecto de Ley de Excepciones) to modify current Copyright Act no.11.723 of 1933. One wonders whether it would be better to draft from scratch a modern Copyright Act instead of patching up the old 1933 Act. Nevertheless, the bill is welcomed. Argentina, as this author has already expressed, has one of the most restrictive copyright laws in the world (see Propuestas para ampliar el acceso a los bienes públicos en Argentina – Estableciendo el necesario balance entre derechos de propiedad intelectual y dominio público, Maximiliano Marzetti, Buenos Aires, 2013).
Resistance to high prices for hepatitis C drugs is ongoing as five new challenges against patents have been filed in India and Argentina, according to sources. Those challenges aim at allowing the production and distribution of affordable generic versions of new hepatitis C medicines (direct-acting antivirals).